These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 28639750)
1. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization. Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750 [TBL] [Abstract][Full Text] [Related]
2. SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Yoshioka Y; Suzuki T; Matsuo Y; Nakakido M; Tsurita G; Simone C; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R Oncotarget; 2016 Nov; 7(46):75023-75037. PubMed ID: 27626683 [TBL] [Abstract][Full Text] [Related]
3. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881 [TBL] [Abstract][Full Text] [Related]
4. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819 [TBL] [Abstract][Full Text] [Related]
5. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Van Aller GS; Reynoird N; Barbash O; Huddleston M; Liu S; Zmoos AF; McDevitt P; Sinnamon R; Le B; Mas G; Annan R; Sage J; Garcia BA; Tummino PJ; Gozani O; Kruger RG Epigenetics; 2012 Apr; 7(4):340-3. PubMed ID: 22419068 [TBL] [Abstract][Full Text] [Related]
6. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. Kim H; Heo K; Kim JH; Kim K; Choi J; An W J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295 [TBL] [Abstract][Full Text] [Related]
7. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609 [TBL] [Abstract][Full Text] [Related]
8. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription. Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385 [TBL] [Abstract][Full Text] [Related]
9. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway. Colón-Bolea P; Crespo P Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779 [TBL] [Abstract][Full Text] [Related]
10. Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy. Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y; Fan Y Tumour Biol; 2016 Jun; 37(6):7371-81. PubMed ID: 26676636 [TBL] [Abstract][Full Text] [Related]
11. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer. Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356 [TBL] [Abstract][Full Text] [Related]
12. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance. Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925 [TBL] [Abstract][Full Text] [Related]
13. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cock-Rada AM; Medjkane S; Janski N; Yousfi N; Perichon M; Chaussepied M; Chluba J; Langsley G; Weitzman JB Cancer Res; 2012 Feb; 72(3):810-20. PubMed ID: 22194464 [TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749 [TBL] [Abstract][Full Text] [Related]
15. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345 [TBL] [Abstract][Full Text] [Related]
16. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase. Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412 [TBL] [Abstract][Full Text] [Related]
17. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013 [TBL] [Abstract][Full Text] [Related]
18. [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2]. Xu JY; Chen LB; Xu JY; Yang Z; Wei HY; Xu RH Ai Zheng; 2006 May; 25(5):526-32. PubMed ID: 16687068 [TBL] [Abstract][Full Text] [Related]
19. SMYD3: a regulator of epigenetic and signaling pathways in cancer. Bernard BJ; Nigam N; Burkitt K; Saloura V Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115 [TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells. Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]